Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Cedirogant in moderate to severe psoriasis
NCT05044234Phase 2Terminated
- Sponsor
- AbbVie Inc.
- Start
- Nov 2021
- Primary completion
- Nov 2022
- Modality
- Small Molecules
- Countries
- 3
01
Overview
A Phase 2 trial of cedirogant in plaque psoriasis, sponsored by AbbVie Inc.. Started Nov 2021; status: terminated.
02
Drugs
cedirogant
03
Conditions
plaque psoriasis
Beyond the preview
Go deeper on NCT05044234.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05044234.